Gabapentin enacarbil
Gabapentin enacarbil (Horizant, XP-13512) is a prodrug for the anticonvulsant and analgesic drug gabapentin.[1] It was designed for increased oral bioavailability over gabapentin,[2][3] and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability,[4] especially when taken with a fatty meal.[5] Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective.[6][7][8]
Gabapentin enacarbil was denied approval by the U.S. Food and Drug Administration (FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk.[9]
On April 6, 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome.[10]
See also
References
- ^ Landmark CJ, Johannessen SI (2008). "Modifications of antiepileptic drugs for improved tolerability and efficacy". Perspectives in Medicinal Chemistry 2: 21–39. PMC 2746576. PMID 19787095. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2746576.
- ^ Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA (October 2004). "XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters". The Journal of Pharmacology and Experimental Therapeutics 311 (1): 315–23. doi:10.1124/jpet.104.067934. PMID 15146028.
- ^ Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (October 2004). "XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys". The Journal of Pharmacology and Experimental Therapeutics 311 (1): 324–33. doi:10.1124/jpet.104.067959. PMID 15146029.
- ^ Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (December 2008). "Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin". Journal of Clinical Pharmacology 48 (12): 1378–88. doi:10.1177/0091270008322909. PMID 18827074.
- ^ Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC (February 2010). "The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil". International Journal of Clinical Pharmacology and Therapeutics 48 (2): 120–8. PMID 20137764.
- ^ Merlino G, Serafini A, Lorenzut S, Sommaro M, Gigli GL, Valente M (January 2010). "Gabapentin enacarbil in restless legs syndrome". Drugs of Today (Barcelona, Spain : 1998) 46 (1): 3–11. doi:10.1358/dot.2010.46.1.1424766. PMID 20200691.
- ^ Bogan RK, Bornemann MA, Kushida CA, Trân PV, Barrett RW (June 2010). "Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study". Mayo Clinic Proceedings. Mayo Clinic 85 (6): 512–21. doi:10.4065/mcp.2009.0700. PMID 20511481.
- ^ Imamura S, Kushida C (August 2010). "Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome". Expert Opinion on Pharmacotherapy 11 (11): 1925–32. doi:10.1517/14656566.2010.494598. PMID 20629607.
- ^ GlaxoSmithKline/XenoPort: FDA setback halts gabapentin reformulations
- ^ [1]
|
|
|
Opioids
See also: Opioids template |
|
Opium & alkaloids thereof
|
|
|
|
Semi-synthetic opium
derivatives
|
|
|
|
Synthetic opioids
|
|
|
|
| Pyrazolones |
|
|
| Cannabinoids |
|
|
| Anilides |
|
|
Non-steroidal
anti-inflammatories
See also: NSAIDs template |
|
Propionic acid class
|
|
|
|
Oxicam class
|
|
|
|
Acetic acid class
|
|
|
|
|
|
|
|
Anthranilic acid
(fenamate) class
|
|
|
|
|
|
|
|
Atypical, adjuvant and potentiators,
Metabolic agents and miscellaneous |
|
|
|
|
|
|
|
anat(n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp
|
noco(m/d/e/h/v/s)/cong/tumr, sysi/epon, injr
|
proc, drug(N1A/2AB/C/3/4/7A/B/C/D)
|
|
|
|
|
|
|
| GABAA receptor agonist |
|
|
| Other GABA agents |
|
|
| Carbonic anhydrase inhibitor |
|
|
| Channel blockers |
|
|
| Channel openers |
|
|
| Indirect GABA agents |
|
|
Unknown/multiple/
unsorted |
|
|
|
|
anat(n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp
|
noco(m/d/e/h/v/s)/cong/tumr, sysi/epon, injr
|
proc, drug(N1A/2AB/C/3/4/7A/B/C/D)
|
|
|
|